Document is current
Any future updates will be listed below
-
Authors
Kiourtis, Christos https://orcid.org/0000-0002-6682-5668
Terradas-Terradas, Maria https://orcid.org/0000-0002-3823-8968
Gee, Lucy M.
May, Stephanie https://orcid.org/0000-0003-0095-7403
Georgakopoulou, Anastasia https://orcid.org/0000-0001-9328-7466
Collins, Amy L. https://orcid.org/0000-0003-3619-2588
O’Sullivan, Eoin D. https://orcid.org/0000-0002-7709-6595
Baird, David P. https://orcid.org/0000-0002-6338-3788
Hassan, Mohsin
Shaw, Robin
Tan, Ee Hong
Müller, Miryam https://orcid.org/0000-0002-0751-1407
Engelmann, Cornelius
Andreola, Fausto
Hsieh, Ya-Ching
Reed, Lee H.
Borthwick, Lee A.
Nixon, Colin https://orcid.org/0000-0002-8085-2160
Clark, William
Hanson, Peter S.
Sumpton, David https://orcid.org/0000-0002-9004-4079
Mackay, Gillian
Suzuki, Toshiyasu https://orcid.org/0000-0002-2711-0360
Najumudeen, Arafath K. https://orcid.org/0000-0002-3764-5721
Inman, Gareth J. https://orcid.org/0000-0002-6264-4253
Campbell, Andrew https://orcid.org/0000-0003-3930-1276
Barry, Simon T. https://orcid.org/0000-0002-8511-0588
Quaglia, Alberto
Morris, Christopher M. https://orcid.org/0000-0002-3749-0993
LeBeau, Fiona E. N.
Sansom, Owen J. https://orcid.org/0000-0001-9540-3010
Kirschner, Kristina https://orcid.org/0000-0001-7607-8670
Jalan, Rajiv https://orcid.org/0000-0002-7747-4015
Oakley, Fiona https://orcid.org/0000-0001-8692-1836
Bird, Thomas G. https://orcid.org/0000-0002-6120-1581
-
Funding
Funding for this research was provided by:
Wellcome Trust (WT107492Z, 226202/Z/22/Z)
Cancer Research UK (A21139, A26813, A17196, A31287, A17196, A17196, A31287, A17196, A17196, A31287, A17196, A31287, A17196, A31287, A25045, A26813, A17196, A31287, A17196, A31287, A29802)
RCUK | Medical Research Council (MR/Y003365/1, MR/N013166/1, MR/K0019494/1, MR/K0019494/1, MR/X004112/1, MR/X004112/1, MR/W00089X/1, MR/K0019494/1)
DH | National Institute for Health Research (HPRU-2012-10076, HPRU-2012-10076)
Wellcome Trust (WT107492Z)
Rosetrees Trust (PGL22/100014, PGL22/100014)
RCUK | MRC | Medical Research Foundation (MR/Y003365/1, MR/R006237/1, MR/X008304/1)
John Goldman Fellowship sponsored by Leukaemia U.K.
Brains for Dementia
William Harker Foundation
Queensland Health Targeted Clinical Research Fellowship and Metro North Clinical Research Fellowship Queensland
EC | Horizon 2020 Framework Programme (945096, 945096, 945096, 945096, 945096)
- License Information
-
More Information
Article History
Received: 23 July 2024
Accepted: 20 September 2024
First Online: 13 November 2024
Competing interests
: S.T.B. is an employee and shareholder of AstraZeneca. L.A.B. and F.O. are directors, employees and shareholders of Fibrofind, and L.H.R. is an employee and shareholder of Fibrofind. A patent entitled ‘Agents for use in a method of treating an acute liver disease’ has been filed in relation to the work associating senescence markers with patient outcomes; patent applicants: Beatson Institute for Cancer Research, University College London, Royal Free London NHS Foundation Trust, Charité – Universitätsmedizin Berlin; inventor(s)—T.G.B., F.A., R.J. and A.Q. (application number 2309181.2). R.J. is the inventor of OPA, which has been patented by UCL and licensed to Mallinckrodt Pharma. He is also the founder of Yaqrit Limited, Hepyx Limited (spin out companies from University College London) and Cyberliver. He has research collaborations with Yaqrit Limited. The other authors do not have competing interests to declare.
